Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors

Deschaseaux, Frédéric; Selmani, Zohair; Falcoz, Pierre‐Emmanuel; Mersin, Nursen; Meneveau, Nicolas; Penfornis, A.; Kleinclauss, C.; Chocron, Sidney; Etievent, Joseph-Philippe; Tiberghien, Pierre; Kantelip, Jean-Pierre; Davani, Siamak

doi:10.1016/j.ejphar.2007.01.045

Cited by 65 publications

(42 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this is possibly explained by the low number of CD34+ cells co-expressing VEGFR-2 in both groups studied. Deschaseaux and colleagues suggest that the phenotype CD34+VE-cadherin+ is a more specific marker than CD34+VEGFR-2+ for detection of late or mature circulating EPCs in blood [44].…”

Section: Discussionmentioning

confidence: 99%

Circulating endothelial progenitor cells, endothelial function, carotid intima–media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria

et al. 2009

View full text Add to dashboard Cite

Aims/hypothesis Type 1 diabetes is associated with premature arterial disease. Bone-marrow derived, circulating endothelial progenitor cells (EPCs) are believed to contribute to endothelial repair. The hypothesis tested was that circulating EPCs are reduced in young people with type 1 diabetes without vascular injury and that this is associated with impaired endothelial function and increased carotid intima-media thickness (CIMT). Methods We compared 74 people with type 1 diabetes with 80 healthy controls. CD34, CD133, vascular endothelial (VE) growth factor receptor-2 (VEGFR-2) and VE-cadherin antibodies were used to quantify EPCs and progenitor cell subtypes using flow-cytometry. Ultrasound assessment of endothelial function by brachial artery flow-mediated dilatation (FMD) and CIMT was made. Circulating endothelial markers, inflammatory markers and plasma plasminogen activator inhibitor-1 (PAI-1) levels were measured. Results CD34+VE-cadherin+, CD133+VE-cadherin+ and CD133+VEGFR-2+ EPC counts were significantly lower in people with diabetes (46-69%; p=0.004-0.043). In people with type 1 diabetes, FMD was reduced by 45% (p<0.001) and CIMT increased by 25% (p<0.001), these being correlated (r=−0.25, p=0.033). There was a significant relationship between FMD and CD34+VE-cadherin+ (r = 0.39, p = 0.001), CD133+VEGFR-2+ (r =0.25, p = 0.037) and CD34+ (r=0.34, p=0.003) counts. Circulating high-sensitivity C-reactive protein, PAI-1, interleukin-6 and E-selectin were significantly higher in the diabetes group (p < 0.001 to p = 0.049), the last two of these correlating with FMD (r=−0.27, p=0.028 and r=−0.24, p=0.048, respectively). Conclusions/interpretation These findings suggest that abnormalities of endothelial function in addition to proinflammatory and pro-thrombotic states are already common in people with type 1 diabetes before development of clinically evident arterial damage. Low EPC counts confirm risk of macrovascular complications and may account for impaired endothelial function and predict future cardiovascular events.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating endothelial progenitor cells, endothelial function, carotid intima–media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Statins promote the mobilization of hematopoietic progenitor cells from the bone marrow and increase EPC proliferation, survival, and functional activity Llevadot et al, 2001). Statins increased EPC levels with a peak at 3 to 4 weeks of treatment , whereas a treatment Ͼ4 weeks augmented the late EPC population, which displays higher proliferative potential than early EPC subset (Deschaseaux et al, 2007). Intensive statin treatments (80 versus 20 mg of atorvastatin) have been associated with higher EPC numbers (Leone et al, 2008), whereas longer standard therapeutic regimens (Ͼ8 weeks) have been associated with a reduction in EPC count in the peripheral blood (Hristov et al, 2007), probably because of the increased incorporation of the mobilized EPC into injury sites.…”

Section: Statins and Endothelial Progenitor Cell Biologymentioning

confidence: 95%

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Gazzerro

Proto²,

Gangemi³

et al. 2011

Pharmacol Rev

401

370

View full text Add to dashboard Cite

“…Besides modifying LDL-C levels, statins have pleiotropic effects that protect the vascular endothelium and prevent the formation of atherosclerotic plaques. Statins improve endothelial functions in hyperlipidemic diabetic patients in the long term [6]. Restoring endothelial functions may prevent cardiovascular disease and may reduce the mortality from diabetes.…”

mentioning

confidence: 99%

Short Term Effects of Atorvastatin on Endothelial Functions and Oxidized LDL Levels in Patients with Type 2 Diabetes

et al. 2008

View full text Add to dashboard Cite

Abstract. Objective: This study was designed in order to investigate the short term effects of atorvastatin on endothelial function and oxidized LDL (oxLDL) levels and to evaluate the association of endothelial dysfunction to oxLDL levels and inflammatory markers in type 2 diabetic patients. Material and Methods: Thirty type 2 diabetic and 11 healthy subjects with LDL levels between 100-160 mg/dl. without a history of cardiovascular event were included in the study. Both groups were matched with respect to age, gender, body mass indices and lipid levels. Flow-mediated dilatation (endothelium dependent, FMD) and nitroglycerine-induced dilatation (endothelium independent, NID) were measured in the brachial artery using high-resolution ultrasound in all participants and carotid artery intima media thickness (IMT) were also evaluated. OxLDL levels, lipid parameters, blood glucose, C-peptide, HbA1c and inflammatory markers including C-reactive protein (CRP), fibrinogen, erythrocyte sedimentation rate (ESR) were studied. Type 2 diabetic patients received 10 mg. Atorvastatin for 6 weeks and FMD and NID were reevaluated and oxLDL levels and inflammatory markers remeasured. Results: Basal FMD, NID, IMT and oxLDL levels besides inflammatory markers were not significantly different between patients and controls. No correlation was found between inflammatory markers and FMD and NID. Only IMT correlated with fibrinogen levels obtained before treatment. In non-diabetics, IMT also correlated with oxLDL levels (p: 0.013). FMD and NID significantly improved after atorvastatin therapy ((7.62 ± 7.6 vs. 12.65 ± 7.8, p<0.001 and 18.22 ± 9.57 vs. 21.43 ± 9.6, p: 0.007, respectively). Atorvastatin significantly reduced oxLDL levels (57.85 ± 10.33 vs. 44.36 ± 6.34, p<0.001). Conclusion: Atorvastatin improves endothelial functions and reduces oxLDL levels in type 2 diabetics with average lipid levels in the short term and may have beneficial effects in the prevention of early atherosclerotic changes.

show abstract

Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors

Cited by 65 publications

References 22 publications

Circulating endothelial progenitor cells, endothelial function, carotid intima–media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria

Circulating endothelial progenitor cells, endothelial function, carotid intima–media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Short Term Effects of Atorvastatin on Endothelial Functions and Oxidized LDL Levels in Patients with Type 2 Diabetes

Contact Info

Product

Resources

About